Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACRS | Aclaris Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-1.55 Insider Own0.20% Shs Outstand70.63M Perf Week-14.75%
Market Cap511.64M Forward P/E- EPS next Y-1.86 Insider Trans8.85% Shs Float64.88M Perf Month-9.55%
Income-105.30M PEG- EPS next Q-0.48 Inst Own96.50% Short Float / Ratio8.79% / 8.11 Perf Quarter-33.33%
Sales31.20M P/S16.40 EPS this Y16.80% Inst Trans0.38% Short Interest5.70M Perf Half Y-13.67%
Book/sh2.54 P/B2.69 EPS next Y-3.90% ROA-42.70% Target Price31.14 Perf Year-52.27%
Cash/sh1.60 P/C4.27 EPS next 5Y- ROE-54.40% 52W Range5.77 - 18.96 Perf YTD-56.70%
Dividend- P/FCF- EPS past 5Y11.80% ROI-45.50% 52W High-64.03% Beta0.68
Dividend %- Quick Ratio5.80 Sales past 5Y77.60% Gross Margin57.70% 52W Low18.20% ATR0.48
Employees105 Current Ratio5.80 Sales Q/Q26.70% Oper. Margin- RSI (14)35.21 Volatility7.39% 6.75%
OptionableYes Debt/Eq0.00 EPS Q/Q-34.50% Profit Margin- Rel Volume1.18 Prev Close6.77
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume702.83K Price6.82
Recom1.40 SMA20-8.65% SMA50-20.41% SMA200-36.55% Volume831,490 Change0.74%
Date Action Analyst Rating Change Price Target Change
Dec-14-22Initiated Stifel Buy $29
Dec-01-22Initiated Goldman Buy $25
Oct-06-22Initiated BTIG Research Buy $32
Jul-23-21Resumed Jefferies Buy $27 → $32
Jun-15-21Initiated Piper Sandler Overweight $30
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Nov-02-15Initiated Citigroup Buy
Sep-20-23 07:00AM
Sep-18-23 07:00AM
Sep-14-23 07:03PM
Sep-08-23 05:06PM
Aug-10-23 06:07AM
08:40AM Loading…
Aug-08-23 08:40AM
Aug-07-23 08:15AM
Aug-01-23 07:53AM
Jul-06-23 08:19AM
Jun-26-23 10:15AM
Jun-13-23 06:30PM
Jun-02-23 07:00AM
01:50PM Loading…
May-18-23 01:50PM
May-10-23 06:04AM
May-08-23 11:55PM
May-05-23 06:49AM
May-02-23 07:01AM
Apr-27-23 04:35AM
Apr-24-23 02:37PM
Apr-04-23 07:40AM
Mar-27-23 07:00AM
Mar-10-23 11:34AM
Mar-06-23 03:59PM
01:03PM Loading…
Feb-23-23 08:35AM
Feb-22-23 06:01AM
Feb-09-23 04:01PM
Jan-06-23 07:01AM
Nov-29-22 07:00AM
Nov-26-22 01:39PM
Nov-22-22 04:01PM
Nov-16-22 12:10PM
Nov-10-22 04:01PM
Nov-08-22 08:25AM
Oct-26-22 06:44AM
Sep-27-22 07:00AM
Sep-15-22 06:46AM
Aug-30-22 07:00AM
Aug-25-22 07:00AM
Aug-05-22 07:59AM
Aug-03-22 08:25AM
Aug-01-22 07:00AM
Jul-15-22 12:00PM
Jul-08-22 09:40AM
Jul-01-22 09:36AM
Jun-27-22 07:00AM
Jun-22-22 09:40AM
Jun-20-22 08:20AM
Jun-13-22 09:55AM
Jun-06-22 09:40AM
Jun-01-22 04:01PM
May-27-22 09:55AM
May-17-22 11:53AM
May-16-22 07:00AM
May-10-22 08:15AM
May-04-22 07:35PM
May-03-22 07:00AM
May-02-22 06:10AM
Apr-13-22 12:17AM
Feb-24-22 08:55AM
Feb-21-22 04:34AM
Feb-17-22 03:03PM
Feb-06-22 04:33PM
Feb-02-22 07:00AM
Feb-01-22 04:01PM
Jan-11-22 04:01PM
Dec-27-21 07:00AM
Dec-20-21 05:21PM
Dec-08-21 11:59AM
Dec-03-21 07:00AM
Nov-23-21 04:13AM
Nov-18-21 04:01PM
Nov-03-21 07:00AM
Nov-02-21 08:25AM
Oct-27-21 03:03PM
Oct-12-21 07:16PM
Sep-29-21 08:47AM
Sep-20-21 08:00AM
Aug-26-21 04:01PM
Aug-25-21 06:16AM
Aug-05-21 10:58AM
Jul-30-21 03:00PM
Jul-08-21 07:00AM
Jul-06-21 11:49AM
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Balthaser KevinChief Financial OfficerSep 06Buy7.909,49074,97115,461Sep 07 04:16 PM
Loerop JamesChief Business OfficerAug 28Buy6.8014,70599,95921,688Aug 28 04:39 PM
Monahan JosephChief Scientific OfficerAug 21Sale7.326,00043,895135,724Aug 22 04:31 PM
Molineaux Christopher P.DirectorJun 20Option Exercise1.4116,50023,26548,503Jun 22 04:32 PM
Monahan JosephChief Scientific OfficerJun 20Sale10.286,00061,663141,724Jun 22 04:30 PM
Molineaux Christopher P.DirectorJun 15Option Exercise1.3624933832,003Jun 20 04:31 PM
Manion Douglas J.Pres and CEOMar 17Buy7.866,30049,53212,800Mar 17 05:03 PM
Manion Douglas J.Pres and CEOMar 09Buy7.746,50050,2786,500Mar 09 05:56 PM
Walker NealDirectorMar 03Sale12.6330,240382,0701,273,202Mar 03 08:37 PM
Monahan JosephChief Scientific OfficerMar 03Sale12.6316,037202,615147,724Mar 03 08:12 PM
Balthaser KevinChief Financial OfficerMar 03Sale12.6389411,2905,256Mar 03 08:09 PM
Walker NealDirectorMar 02Sale12.3729,000358,5881,285,188Mar 03 08:37 PM
Monahan JosephChief Scientific OfficerMar 02Sale12.3714,800183,024151,261Mar 03 08:12 PM
Balthaser KevinChief Financial OfficerMar 02Sale12.291,00012,2894,650Mar 03 08:09 PM
Monahan JosephChief Scientific OfficerFeb 15Sale13.065,00065,31091,386Feb 17 04:34 PM
Loerop JamesChief Business OfficerFeb 08Sale13.894,26759,2726,983Feb 10 04:55 PM
Walker NealDirectorFeb 02Sale16.255,00081,2481,175,763Feb 03 05:09 PM
Walker NealDirectorFeb 01Sale16.7525,000418,6751,180,763Feb 03 05:09 PM
Walker NealDirectorJan 04Sale14.8915,000223,3421,205,763Jan 04 06:20 PM
Walker NealDirectorJan 03Sale15.2525,000381,2131,220,763Jan 04 06:20 PM
Monahan JosephChief Scientific OfficerDec 15Sale15.885,00079,41296,386Dec 16 04:57 PM
SCHIFF ANDREW NDirectorNov 14Sale17.081,37123,417434,455Nov 14 04:51 PM
SCHIFF ANDREW NDirectorNov 11Sale17.0641,160702,177435,826Nov 14 04:51 PM
SCHIFF ANDREW NDirectorNov 10Sale17.0211,395193,995476,986Nov 14 04:51 PM
SCHIFF ANDREW NDirectorOct 26Sale17.0014,540247,253488,381Oct 26 07:09 PM
SCHIFF ANDREW NDirectorOct 25Sale17.0212,018204,516502,921Oct 26 07:09 PM
SCHIFF ANDREW NDirectorOct 24Sale17.0114,616248,586514,939Oct 26 07:09 PM
SCHIFF ANDREW NDirectorOct 18Sale16.8932,093542,022529,555Oct 19 04:49 PM
SCHIFF ANDREW NDirectorOct 17Sale16.0519,944320,087561,648Oct 19 04:49 PM
Monahan JosephChief Scientific OfficerOct 17Sale15.985,00079,908101,386Oct 19 04:45 PM
SCHIFF ANDREW NDirectorOct 07Sale16.167,324118,349581,592Oct 11 04:35 PM
SCHIFF ANDREW NDirectorOct 06Sale16.5437,839625,744588,916Oct 06 05:58 PM
SCHIFF ANDREW NDirectorOct 04Sale16.017,700123,259626,755Oct 06 05:58 PM